含洛铂的联合方案治疗晚期转移性乳腺癌的临床研究

A Clinical Study of Combination Regimen Containing Lobaplatin in Treating Advanced Metastatic Breast Cancer

目的：分析含洛铂的联合化疗方案在晚期转移性乳腺癌治疗中的疗效及不良反应。方法：收集2013年1月～2016年1月54例就诊于山西省肿瘤医院发生转移的乳腺癌患者,给予含洛铂（30 mg/m2）的联合方案化疗,21 d为1个周期,至少进行2个周期。应用RECIST1.1版评价疗效,根据NCI-CTC4.0版对毒副反应分级。结果：54例患者均可评价治疗效果和不良反应。2例CR,33例PR,15例SD,4例PD,有效率为64.8%,疾病控制率为92.6%。主要方案为长春瑞滨＋洛铂22例,多西他赛＋洛铂23例,有效率分别为59.1%vs.69.6%,疾病控制率为86.4%vs.95.7%,差异无统计学意义（P〉0.05）。不良反应骨髓抑制较为严重,经过治疗后一般能缓解,其余不良反应还有恶心呕吐、身体疲乏和口腔溃疡等。结论：含洛铂的联合方案治疗晚期转移性乳腺癌疗效好,不良反应较轻,值得推广。

Objective： To analyze the efficacy and adverse drug reaction of combination regimen containing Lobaplatin in treating advanced metastatic breast cancer. Methods： 54 patients who diagnosed as metastatic breast cancer at Tumor Hospital of Shanxi Province From January 2013 to January 2016 were selected as the experimental cases. Lobaplatin and other drugs as a chemotherapeutic method were given to these patients. Twenty-one days was a cycle. The efficacy and adverse drug reaction were estimated after at least two cycles of chemotherapy. Tumor evaluation was performed according to RECIST. According to National Cancer Institute Common Toxicity Criteria the toxicity were divided into several levels. Results： All these patients could be evaluated efficacy and adverse reactions with 2 cases of CR,33 cases of PR,15 cases of SD,4 cases of PD. The response rate（ RR） was 64. 8%,and the disease control rate（ DCR）was 92. 6%. The major treatments were Navelbine with Lobaplatin（ NP） and Docetaxel with Lobaplatin（ DP）,in which22 patients used NP and 23 patients used TP. The RR was 59. 1% vs. 69. 6%,and the DCR was 86. 4% vs. 95. 7%.There was no statistical significant difference（ P〉0. 05）. The major toxicity was bone marrow suppression and it usually could be cured under relevant treatments. There were other adverse reactions like nausea and vomiting,oral ulcer tired body,etc. Conclusion： Combination regimen containing Lobaplatin can be popularized because it is effective in treating advanced metastatic breast cancer and the adverse reactions can be well tolerate.